Last reviewed · How we verify
daytime dosing of mirabegron
Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity.
Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.
At a glance
| Generic name | daytime dosing of mirabegron |
|---|---|
| Sponsor | Far Eastern Memorial Hospital |
| Drug class | Beta-3 adrenergic receptor agonist |
| Target | Beta-3 adrenergic receptor (ADRB3) |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Mirabegron activates beta-3 adrenergic receptors on the smooth muscle of the bladder detrusor, causing relaxation and increased bladder capacity during the storage phase of the micturition cycle. Unlike anticholinergic agents, it does not block muscarinic receptors, resulting in a different side effect profile. This mechanism allows increased urine storage without affecting bladder emptying.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency
Common side effects
- Hypertension
- Headache
- Tachycardia
- Nasopharyngitis
- Urinary tract infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- daytime dosing of mirabegron CI brief — competitive landscape report
- daytime dosing of mirabegron updates RSS · CI watch RSS
- Far Eastern Memorial Hospital portfolio CI